NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
DOPAMINE HYDROCHLORIDE (dopamine hydrochloride) by AbbVie is clinical pharmacology dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (dopa). Approved for hemodynamic status in patients in shock.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dopamine hydrochloride is a catecholamine IV infusion that acts as a dopamine receptor agonist and beta-1 adrenergic agonist. It is indicated for hemodynamic support in patients in shock, with dose-dependent effects ranging from renal vasodilation at low doses to inotropic support and vasoconstriction at higher doses. The drug has rapid onset (within 5 minutes) and short duration (<10 minutes), requiring continuous IV infusion in acute care settings.
Pre-Launch
Pre-launch status indicates AbbVie is preparing market entry; commercial teams should expect launch readiness activities, market access strategy refinement, and competitive positioning planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal…
Worked on DOPAMINE HYDROCHLORIDE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.